On September 22, 2023, the World Federation of Chinese Doctors and Baheal Pharmaceutical Group jointly initiated the 2023 World Chinese Physicians Conference and the Medical Innovation and Translation Forum in Qingdao, Shandong. This gathering, the first grand ceremony since the pandemic, brought together numerous exceptional representatives of Chinese doctors and scholars from both home and abroad to share the latest accomplishments and innovative trends in global healthcare. As a critical part of this forum, the Baheal Pharmaceutical Group, witnessed by a multitude of experts and academics, signed a contract with Professor Wang Wei, the Vice President of the World Federation of Chinese Doctors and Deputy Principal of Edith Cowan University (ECU) in Australia. They will collaborate to establish a research platform in the realm of glycomics.

Glycomics, an emerging field of biological research following genomics and proteomics, is offering a fresh perspective on our understanding of human health and diseases, receiving marked attention in the academic world. Glycosylation of proteins, a common form of protein post-translational modification, influences protein function and localization. Changes in protein glycosylation are closely associated with aging, as well as major diseases such as malignancies, cardiovascular diseases, autoimmune diseases, and neurodegenerative diseases. Thus, in-depth study of glycosylation modifications is critical for uncovering disease-related biomarkers and drug targets, offering new avenues for the early screening of major diseases and the research and development of new drugs, showing immense potential.

Professor Wang Wei, a globally renowned expert in glycomics and genetic epidemiology, is one of the initiators of the "Human Glycome Project," committed to promoting the development of glycomics worldwide. Pioneeringly, Professor Wang proposed the "Periphery-Central Principle" hypothesis, explaining that sugars can serve as the third life code, following genes and proteins, playing a vital role in cellular life activities. The glycomics research team at the ECU School of Medicine and Health Sciences, led by him, has achieved a series of significant breakthroughs. Starting with this signing, Professor Wang and his team will complement Baheal's advantages, jointly deepening research in the field related to glycomics, promoting the development of the discipline and the transformation of achievements.

The evolution and progress of medicine are inseparable from breakthroughs in biology, as it uncovers the causal laws behind diseases, providing key insights for scientists and medical experts to develop more effective treatment methods. Baheal, as an industry investor deeply engaged in the medical and health sector, profoundly acknowledges the critical role of fundamental biological studies in propelling medical progress. As a result, Baheal has been consistently ramping up its investments in establishing fundamental research platforms in recent years, steering both molecular and immunological research and results transformation platforms. They've made significant breakthroughs in early screening for severe diseases and accompanying drug diagnoses, actualizing the transformation and application of their products and services on the ground.

This collaboration with Professor Wang Wei in the field of glycomics will further enhance the innovative layout of Baheal's basic research platform. Through ecological synergy, it will effectively promote the development of basic biological research, stimulate original innovation, achieve breakthrough results in proprietary intellectual property rights, and truly benefit patients.

Baheal has not only made strategic layouts in fundamental research platforms but has also accomplished innovative transformations in the field of innovative drugs and high-end medical devices, establishing an ecosystem that supports medical innovation industrialization. Leveraging their industrial resource advantages in the health and medical field, as well as the synergy of an ecosystem-based organization, Baheal meticulously guides the entire process of medical innovation transformation. They provide resource allocation for scientists and innovative enterprises, assisting the rapid implementation and conversion of innovative results, introducing them into the market, and effectively optimizing healthcare scenarios.

In the future, Baheal Pharmaceutical Group will continue to focus on unfulfilled clinical needs, pursuing breakthroughs in fundamental cutting-edge research to advance key core technologies, and speeding up the drive for medical innovation. The group is committed to carrying out its corporate mission of "Optimizing healthcare scenarios through technological innovation."